Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Buy
58
AZN Quote, Financials, Valuation and Earnings
Last price:
$73.00
Seasonality move
:
3.56%
Day range:
$72.41 - $73.39
52-week range:
$61.24 - $87.68
Dividend yield:
2.12%
P/E ratio:
29.32x
P/S ratio:
4.15x
P/B ratio:
5.52x
Volume:
3.6M
Avg. volume:
5.2M
1-year change:
-8.77%
Market cap:
$226.3B
Revenue:
$54.1B
EPS (TTM):
$2.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.12 | 8.83% | 84.16% | $84.18 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.67% | 279.07% | $314.70 |
|
BNTX
BioNTech SE
|
$183.4M | -$2.66 | 17.63% | -35.99% | $133.41 |
|
GILD
Gilead Sciences
|
$6.8B | $1.77 | -0.13% | 51.38% | $115.42 |
|
GSK
GSK PLC
|
$10B | $1.04 | 5.94% | 60.08% | $41.54 |
|
MRNA
Moderna
|
$115.3M | -$3.11 | -49.84% | -11.55% | $47.70 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$73.00 | $84.18 | $226.3B | 29.32x | $1.05 | 2.12% | 4.15x |
|
AMGN
Amgen
|
$287.01 | $314.70 | $154.3B | 26.19x | $2.38 | 3.23% | 4.55x |
|
BNTX
BioNTech SE
|
$111.15 | $133.41 | $26.7B | 191.55x | $0.00 | 0% | 9.01x |
|
GILD
Gilead Sciences
|
$109.02 | $115.42 | $135.6B | 22.95x | $0.79 | 2.84% | 4.78x |
|
GSK
GSK PLC
|
$40.80 | $41.54 | $82.9B | 21.16x | $0.43 | 3.92% | 2.10x |
|
MRNA
Moderna
|
$27.81 | $47.70 | $10.8B | -- | $0.00 | 0% | 3.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.02% | 0.266 | 13.05% | 0.69x |
|
AMGN
Amgen
|
90.24% | -0.159 | 34.26% | 0.74x |
|
BNTX
BioNTech SE
|
1.53% | 1.010 | 1.45% | 9.86x |
|
GILD
Gilead Sciences
|
56.56% | 0.302 | 17.9% | 1.00x |
|
GSK
GSK PLC
|
56.56% | -0.335 | 30.39% | 0.58x |
|
MRNA
Moderna
|
-- | -0.658 | -- | 3.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.3B | $3.7B | 10.93% | 19.55% | 27.61% | $2.7B |
|
AMGN
Amgen
|
$5.2B | $1.2B | 8.85% | 97.08% | 33.08% | $980M |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
GILD
Gilead Sciences
|
$5.1B | $2.5B | 13.82% | 32.29% | 28.63% | $1.7B |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.23%. AstraZeneca PLC's return on equity of 19.55% beat Amgen's return on equity of 97.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B AMGNAmgen63.58% $3.20 $63.6B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Amgen has an analysts' consensus of $314.70 which suggests that it could grow by 9.65%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 AMGNAmgen10 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Amgen has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.15%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Amgen offers a yield of 3.23% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. AstraZeneca PLC's net income of $2.9B is higher than Amgen's net income of $1.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Amgen's PE ratio is 26.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 4.55x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.15x 29.32x $13.6B $2.9B AMGNAmgen4.55x 26.19x $8.1B $1.7B
-
Which has Higher Returns AZN or BNTX?
BioNTech SE has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -227.46%. AstraZeneca PLC's return on equity of 19.55% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About AZN or BNTX?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand BioNTech SE has an analysts' consensus of $133.41 which suggests that it could grow by 20.04%. Given that BioNTech SE has higher upside potential than AstraZeneca PLC, analysts believe BioNTech SE is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 BNTXBioNTech SE14 5 0 -
Is AZN or BNTX More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.
-
Which is a Better Dividend Stock AZN or BNTX?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BNTX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than BioNTech SE quarterly revenues of $192.3M. AstraZeneca PLC's net income of $2.9B is higher than BioNTech SE's net income of -$437.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 9.01x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.15x 29.32x $13.6B $2.9B BNTXBioNTech SE9.01x 191.55x $192.3M -$437.5M
-
Which has Higher Returns AZN or GILD?
Gilead Sciences has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 19.72%. AstraZeneca PLC's return on equity of 19.55% beat Gilead Sciences's return on equity of 32.29%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B GILDGilead Sciences76.9% $1.04 $44B -
What do Analysts Say About AZN or GILD?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Gilead Sciences has an analysts' consensus of $115.42 which suggests that it could grow by 5.87%. Given that AstraZeneca PLC has higher upside potential than Gilead Sciences, analysts believe AstraZeneca PLC is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 GILDGilead Sciences15 11 0 -
Is AZN or GILD More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.86%.
-
Which is a Better Dividend Stock AZN or GILD?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.
-
Which has Better Financial Ratios AZN or GILD?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Gilead Sciences quarterly revenues of $6.7B. AstraZeneca PLC's net income of $2.9B is higher than Gilead Sciences's net income of $1.3B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Gilead Sciences's PE ratio is 22.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 4.78x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.15x 29.32x $13.6B $2.9B GILDGilead Sciences4.78x 22.95x $6.7B $1.3B
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.61%. AstraZeneca PLC's return on equity of 19.55% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand GSK PLC has an analysts' consensus of $41.54 which suggests that it could grow by 1.8%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 GSKGSK PLC1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.283%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. GSK PLC offers a yield of 3.92% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. AstraZeneca PLC's net income of $2.9B is higher than GSK PLC's net income of $2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while GSK PLC's PE ratio is 21.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 2.10x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.15x 29.32x $13.6B $2.9B GSKGSK PLC2.10x 21.16x $9.5B $2B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -907.48%. AstraZeneca PLC's return on equity of 19.55% beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 71.51%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 MRNAModerna5 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $107M. AstraZeneca PLC's net income of $2.9B is higher than Moderna's net income of -$971M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 3.45x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.15x 29.32x $13.6B $2.9B MRNAModerna3.45x -- $107M -$971M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock High Risk or High Reward?
EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…
Why Did Chase Coleman Buy TSM?
Billionaire Chase Coleman of Tiger Global Management has built a…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
80
GWRE alert for Jun 5
Guidewire Software [GWRE] is up 16.33% over the past day.
Buy
60
REVG alert for Jun 5
REV Group [REVG] is up 15.05% over the past day.
Buy
55
SIG alert for Jun 5
Signet Jewelers [SIG] is down 0.96% over the past day.
